Investigational α-synuclein aggregation inhibitors hope for Parkinson’s disease /
Introduction: The therapeutic management of Parkinson’s disease (PD) is challenging and has not been fully resolved. The main challenges include motor fluctuations and levodopa-induced dyskinesia. Moreover, no disease-modifying or neuroprotective therapy is currently available. Areas covered: This r...
Elmentve itt :
Szerzők: |
Török Nóra Majláth Zsófia Szalárdy Levente Vécsei László |
---|---|
Dokumentumtípus: | Cikk |
Megjelent: |
2016
|
Sorozat: | EXPERT OPINION ON INVESTIGATIONAL DRUGS
25 No. 11 |
doi: | 10.1080/13543784.2016.1237501 |
mtmt: | 3132521 |
Online Access: | http://publicatio.bibl.u-szeged.hu/9938 |
Hasonló tételek
-
Thymoquinone prevents neurodegeneration against MPTP in vivo model of Parkinson's disease and modulates α-synuclein aggregation in vitro [abstract] /
Szerző: Ardah Mustafa T., et al.
Megjelent: (2019) -
Aggregation studies, design and synthesis of amyloid aggregation inhibitors for the treatment of Alzheimer's disease
Szerző: Fülöp Lívia
Megjelent: (2005) -
Diffusion Kurtosis Imaging Detects Microstructural Alterations in Brain of α-Synuclein Overexpressing Transgenic Mouse Model of Parkinson’s Disease A Pilot Study /
Szerző: Khairnar Amit, et al.
Megjelent: (2015) -
Monoamine oxidase B inhibitors in Parkinson’s disease
Szerző: Dézsi Livia, et al.
Megjelent: (2017) -
Neuroprotection in Parkinson's disease facts and hopes /
Szerző: Salamon András, et al.
Megjelent: (2020)